Exendin and exendin agonists for eating disorders

Abstract

Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.

1 . A method for treating a condition associated with hypernutrition or reducing the cardiac risk in a human in need thereof comprising administering to the human a therapeutically effective amount of an exendin peptide or an exendin agonist analog peptide to treat the condition associated with hypernutrition or reduce the cardiac risk in the human. 
     
     
         2 . The method of  claim 1  for treating the condition associated with hypernutrition in the human in need thereof. 
     
     
         3 . The method of  claim 1  for reducing the cardiac risk in the human in need thereof. 
     
     
         4 . The method of  claim 1 , wherein the exendin peptide or the exendin agonist analog peptide is exendin-4. 
     
     
         5 . The method of  claim 1 , wherein the exendin peptide or the exendin agonist analog peptide comprises an amino acid sequence of any one of SEQ ID NOs:1-188. 
     
     
         6 . The method of  claim 1 , further comprising administering a therapeutically effective amount of an amylin, an amylin agonist, a leptin, a calcitonin, a cholecystokinin, or a combination of two or more thereof. 
     
     
         7 . The method of  claim 1 , further comprising administering a therapeutically effective amount of pramlintide. 
     
     
         8 . A pharmaceutical formulation comprising exendin-4 and a citrate buffer. 
     
     
         9 . A pharmaceutical formulation comprising an exendin peptide or an exendin agonist analog peptide, wherein the pharmaceutical formulation has a pH from 3.0 to 7.0. 
     
     
         10 . The pharmaceutical formulation of  claim 9 , wherein the exendin peptide or the exendin agonist analog peptide is exendin-4 and the pharmaceutical formulation has a pH from 4.0 to 6.0. 
     
     
         11 . The pharmaceutical formulation of  claim 9  having a pH from 4.0 to 5.0. 
     
     
         12 . The pharmaceutical formulation of  claim 9 , wherein the exendin peptide or the exendin agonist analog peptide comprises an amino acid sequence of any one of SEQ ID NOs:1-188. 
     
     
         13 . The pharmaceutical formulation of  claim 9 , further comprising a buffer selected from the group consisting of an acetate buffer, a phosphate buffer, a citrate buffer, and a glutamate buffer.